Amylyx Pharmaceuticals Inc.

Clinical trials sponsored by Amylyx Pharmaceuticals Inc., explained in plain language.

Amylyx Pharmaceuticals Inc. AMLX NASDAQ

A biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including ALS and Alzheimer's disease.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New ALS drug targets nerve damage in early human trial Results expected Feb 2027 (estimated) May already have reported ↗

Browse trials soon ready across all sponsors →

Trials to join now! 2 Not yet finished but already full! 2 Completed 1

Can a failed ALS drug help PSP patients? new trial results are in

Disease control Completed

This completed Phase 2b/3 trial tested the drug AMX0035 in 139 people with progressive supranuclear palsy (PSP), a rare brain disease that causes problems with balance, movement, and thinking. The study compared the drug to a placebo to see if it could slow the disease. The resul…

Phase 2/3 • Sponsor: Amylyx Pharmaceuticals Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:26 UTC

Amylyx Pharmaceuticals Inc.

Upcoming readouts

Can a failed ALS drug help PSP patients? new trial results are in